<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H75C39F2C0E0643E4948BA1C7705C4260" public-private="public" key="H" bill-type="olc"><form><distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1187</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170216">February 16, 2017</action-date><action-desc><sponsor name-id="S000244">Mr. Sensenbrenner</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To expand the research activities of the National Institutes of Health with respect to functional gastrointestinal and motility disorders, and for other purposes.</official-title></form><legis-body id="H7F1DC1FFB8914B47990BD66C84B9031E" style="OLC"> 
<section id="H3FB3D375C6F34DAD8EDA2B23BFFED2BC" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2017</short-title></quote>.</text></section> <section id="HB3A968AAB68248B2B65A8527D375A7F8"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text>
<paragraph id="H03BE5A2934FD4BE4914DC8BA044A9774"><enum>(1)</enum><text>Functional gastrointestinal and motility disorders (FGIMDs) are chronic conditions associated with increased sensitivity of the GI tract, abnormal motor functioning, and brain-gut dysfunction.</text></paragraph> <paragraph id="HCA6DFBD3A59943DAAA0465A8B2AD26DD"><enum>(2)</enum><text>FGIMDs are characterized by chronic or recurring symptoms in the GI tract including pain or discomfort, nausea, vomiting, diarrhea, constipation, incontinence, problems in the passage of food or feces, or a combination of these symptoms.</text></paragraph>
<paragraph id="H0FB68DE105934595879A5CA32AE49C0A"><enum>(3)</enum><text>FGIMDs include conditions such as functional dysphagia, gastroesophageal reflux disease, dyspepsia, cyclic vomiting syndrome, gallbladder and bile duct dysfunction, gastroparesis, irritable bowel syndrome (IBS), Hirschsprung’s disease, chronic intestinal pseudo-obstruction, bowel incontinence, and many others, which affect the esophagus, stomach, gallbladder, small and large intestine, and anorectal areas of the body.</text></paragraph> <paragraph id="H4585F67D3ACB4C519BB4D5FF0C157401"><enum>(4)</enum><text>The severity of FGIMDs ranges from mildly uncomfortable to debilitating and in some cases life-threatening.</text></paragraph>
<paragraph id="HAA5B529639C242F09F1B8769368A7166"><enum>(5)</enum><text>Effective treatments for the multiple symptoms of FGIMDs are lacking, and while sufferers frequently use a variety of medications and therapies for symptoms, few patients report satisfaction with available treatments.</text></paragraph> <paragraph id="HF32D79821BEB48128743A3BAFE91FCAA"><enum>(6)</enum><text>Physicians are not sufficiently educated on the proper diagnosis and up-to-date treatments for FGIMDs. This leads to excess health care costs due to unneeded diagnostic procedures and errors in treatments.</text></paragraph>
<paragraph id="HE467166757754B75AEAEEDEB240F7AEE"><enum>(7)</enum><text>Patients with FGIMDs frequently suffer for years before receiving an accurate diagnosis, exposing them to unnecessary and costly tests and procedures including surgeries, as well as needless suffering and expense.</text></paragraph> <paragraph id="H4F75B1A02B454A6A8AF12A581A797D10"><enum>(8)</enum><text>The economic impact of FGIMDs is high. The annual cost in the United States for IBS alone is estimated to be between $1.7 billion and $10 billion in direct medical costs (excluding prescription and over-the-counter medications) and $20 billion in indirect medical costs.</text></paragraph>
<paragraph id="H640198DEE24E467FB16E1D67ED7CFBAE"><enum>(9)</enum><text>FGIMDs frequently take a toll on the workplace, as reflected in work absenteeism, lost productivity, and lost opportunities for the individual and society.</text></paragraph> <paragraph id="H3C6823AB052F4B788AFF23B9219FD98C"><enum>(10)</enum><text>Gastrointestinal symptoms consistent with functional gastrointestinal disorders, such as IBS and functional dyspepsia, are recognized as a serious and disabling issue for military veterans, particularly those who have been deployed in war zones.</text></paragraph>
<paragraph id="HD0AA75F73CCE43708C28359FF387A0A7"><enum>(11)</enum><text>FGIMDs affect individuals of all ages including children, and pediatric FGIMDs can be particularly serious, leading to a lifetime of painful symptoms and medical expenses associated with management of chronic illness or death.</text></paragraph> <paragraph id="HA70074B128A549A8BADF0729C3897303"><enum>(12)</enum><text>There is inadequate public education and misunderstanding of FGIMDs leading to stigma placed upon individuals so afflicted.</text></paragraph>
<paragraph id="H1DDC6C1D3A8E4D10B6521B1542552F0D"><enum>(13)</enum><text>The National Institutes of Health’s National Commission on Digestive Diseases identified comprehensive research goals related to FGIMDs in its April 2009 report to Congress and the American public entitled <quote>Opportunities and Challenges in Digestive Diseases Research: Recommendations of the National Commission on Digestive Diseases</quote>.</text></paragraph></section> <section id="H2356EEFCE2E74B229043BC6DB5CC7638"><enum>3.</enum><header>Functional gastrointestinal and motility disorders research enhancement</header><text display-inline="no-display-inline">Part B of the title IV of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/284">42 U.S.C. 284</external-xref> et seq.) is amended by adding at the end the following:</text>
<quoted-block id="H53B04DB32C4B4FFE995043B1EBA344C2" style="OLC">
<section id="HDA1A2DD4F33E487E9390DB8FB930AE8C"><enum>409K.</enum><header>Functional gastrointestinal and motility disorders</header><text display-inline="no-display-inline">The Director of NIH may expand, intensify, and coordinate the activities of the National Institutes of Health with respect to functional gastrointestinal and motility disorders (in this section referred to as <quote>FGIMDs</quote>) by—</text> <paragraph id="H73517FE462114220B472B152ABDD65EF"><enum>(1)</enum><text>expanding basic and clinical research into FGIMDs by implementing the research recommendations of the National Commission on Digestive Diseases relating to FGIMDs;</text></paragraph>
<paragraph id="HAC71B77C984A433D8E9AD6287E57DDF7"><enum>(2)</enum><text>providing support for the establishment of up to five centers of excellence on FGIMDs at leading academic medical centers throughout the country to carry out innovative basic, translational, and clinical research focused on FGIMDs;</text></paragraph> <paragraph id="HA2237A1B26C44661A619170B53C80ED3"><enum>(3)</enum><text>supporting innovative approaches to educating health care providers and patients regarding strategies that improve patient-provider relationships and care and foster research to determine the effects of these approaches in improving patient satisfaction, improved clinical outcomes, efficient utilization of health care services, and reduced health care costs;</text></paragraph>
<paragraph id="HF0F5FE03143643458C6DDC9BB1E5D15D"><enum>(4)</enum><text>exploring collaborative research opportunities among the National Institute of Diabetes and Digestive and Kidney Diseases, the Office of Research on Women’s Health, the Office of Rare Disease Research, and other Institutes and Centers of the National Institutes of Health;</text></paragraph> <paragraph id="HE1C46411D7534B2EB1E0D57512D0D874"><enum>(5)</enum><text>directing the National Institute of Diabetes and Digestive and Kidney Diseases to provide the necessary funding for continued expansion and advancement of the FGIMDs research portfolio through intramural and extramural research;</text></paragraph>
<paragraph id="H0B018E4DEC2F4272A566B2748726BCE5"><enum>(6)</enum><text>directing the National Institute of Diabetes and Digestive and Kidney Diseases and the Eunice Kennedy Shriver National Institute of Child Health and Human Development to expand research into FGIMDs that impact children, such as Hirschsprung’s disease and cyclic vomiting syndrome, and maternal health, such as fecal incontinence; and</text></paragraph> <paragraph id="H5C3DBE13694F4F70B6BADCC2B5BA21F6"><enum>(7)</enum><text>exploring opportunities to partner with the Department of Defense and the Department of Veterans Affairs to increase research and improve patient care regarding FGIMDs that commonly impact veterans and active duty military personnel, such as IBS and dyspepsia.</text></paragraph></section><after-quoted-block>.</after-quoted-block></quoted-block></section>
<section id="H5D8F852DEE104493BB37925D77D2E5C2"><enum>4.</enum><header>Promoting public awareness of functional gastrointestinal and motility disorders</header><text display-inline="no-display-inline"> Part B of title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/243">42 U.S.C. 243</external-xref> et seq.) is amended by adding at the end the following:</text> <quoted-block id="H7AB1FE9BD9A24257985BC89A87367A00" style="OLC"> <section id="HCD5F98BD60034A44A2ACE99F74D212F4"><enum>320B.</enum><header>Public awareness of functional gastrointestinal and motility disorders</header><text display-inline="no-display-inline">The Secretary may engage in public awareness and education activities to increase understanding and recognition of functional gastrointestinal and motility disorders (in this section referred to as <quote>FGIMDs</quote>). Such activities may include the distribution of print, film, and web-based materials targeting health care providers and the public and prepared and disseminated in conjunction with patient organizations that treat FGIMDs. The information expressed through such activities should emphasize—</text>
<paragraph id="HBEFE85BBF99047D582AE0879E006680F"><enum>(1)</enum><text>basic information on FGIMDs, their symptoms, prevalence, and frequently co-occurring conditions; and</text></paragraph> <paragraph id="HC8D8FB4C0FCD456A87F4AB9622C3564E"><enum>(2)</enum><text>the importance of early diagnosis, and prompt and accurate treatment of FGIMDs.</text></paragraph></section><after-quoted-block>.</after-quoted-block></quoted-block></section>
<section id="H206BCB7F7FC6429686110B47F9FB0E2E"><enum>5.</enum><header>Sense of Congress of the development and oversight of innovative treatment options for functional gastrointestinal and motility disorders</header><text display-inline="no-display-inline">It is the sense of Congress that, considering the current lack of effective treatment options for the global symptoms of functional gastrointestinal and motility disorders (in this section referred to as <quote>FGIMDs</quote>) and the inherent challenges of developing and bringing such treatments to market, the Commissioner of Food and Drugs should continue and accelerate important efforts to improve the development and oversight of treatment options for FGIMDs by—</text> <paragraph id="HFC9740D6AA304DDF8D90CC255924EA25"><enum>(1)</enum><text>enhancing the commitment to emerging efforts like the Patient Reported Outcomes Consortium to expedite medical device and drug development, study appropriate balances between risk and patient benefit, and identify proper endpoints for conditions without clear, biological indicators;</text></paragraph>
<paragraph id="H51ACC90EEEAA424FBDBE12B00B67A269"><enum>(2)</enum><text>enhancing the commitment to broad efforts like the Critical Path Initiative focused on ensuring that scientific breakthroughs are quickly translated into safe and beneficial treatment options; and</text></paragraph> <paragraph id="HD253320BC57447B5B1F78785A327B165"><enum>(3)</enum><text>continuing collaboration with patient and provider organizations that treat FGIMDs so that the patient perspective is considered when determining the need for innovative treatments.</text></paragraph></section> 
</legis-body></bill>

